Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | GNRHR | P30968 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4102334 | 0.87 | KIF11 (0.46) | KIF11IDO1GNRHRBRD4MAPT | |
| SCHEMBL5863543 | 0.86 | KIF11 (0.49) | KIF11IDO1GNRHRBRD4SIGMAR1 | |
| SCHEMBL5863338 | 0.86 | KIF11 (0.48) | KIF11GNRHRBRD4MAPTSIGMAR1 | |
| SCHEMBL5863070 | 0.85 | KIF11 (0.48) | KIF11PIK3CA | |
| SCHEMBL5863525 | 0.81 | KIF11 (0.74) | KIF11 | |
| SCHEMBL5863198 | 0.79 | KIF11 (0.42) | KIF11MAPTSIGMAR1SYKTLR7 | |
| SCHEMBL4252742 | 0.77 | KIF11 (0.40) | KIF11GNRHRBRD4MAPTSIGMAR1 | |
| SCHEMBL4252736 | 0.77 | KIF11 (0.40) | KIF11GNRHRBRD4MAPTSIGMAR1 | |
| SCHEMBL4004013 | 0.77 | KIF11 (0.43) | KIF11BRD4MAPTSIGMAR1SYK | |
| SCHEMBL3871323 | 0.77 | KIF11 (0.49) | KIF11BRD4MAPTSIGMAR1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030118-B2 | Pyrrolotriazinone compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | CCNB1, NUMA1, CCNA1 | KIF11 858/4885IDO1 1506/4885GNRHR 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.